Series B · Biotech · Valencia, Spain · Founded 2019 · 10–20 employees
ARTHEx Biotech is a clinical-stage biotechnology company developing innovative RNA medicines that modulate microRNAs for rare genetic neuromuscular disorders. The company's lead program ATX-01 is a first-in-class antimiR therapy targeting microRNA-23b for myotonic dystrophy type 1, currently in Phase I/IIa clinical trials. The company has raised over $95 million in funding including a recent $87 million Series B round led by Bpifrance in September 2025, and has received FDA orphan drug designation for its lead candidate.
No open roles listed right now.